Bladder cancer
- Non–muscle-invasive disease → TURBT ± intravesical therapy
- BCG is central for high-risk non–muscle-invasive disease
- Muscle-invasive disease often needs cisplatin-based chemo + cystectomy
- Bladder-preserving chemoradiation is an alternative in selected cases
- Metastatic disease uses immunotherapy/targeted/antibody-drug therapy
- Stage and urothelial histology drive treatment
Use at a glance
- Non–muscle-invasive disease → TURBT ± intravesical therapy
Treatment options
- Muscle-invasive disease often needs cisplatin-based chemo + cystectomy
- Metastatic disease uses immunotherapy/targeted/antibody-drug therapy
Choosing treatment
- Bladder-preserving chemoradiation is an alternative in selected cases
- Stage and urothelial histology drive treatment
Practical pearls
- BCG is central for high-risk non–muscle-invasive disease
Self-check
- What is initial treatment for non–muscle-invasive bladder cancer?
TURBT ± intravesical therapy.
- What is central for high-risk non–muscle-invasive disease?
BCG.
Drugs used for this (1)
All clinical uses · Open the interactive console ↗
